DK2263669T3 - Farmaceutisk aktive isoindolin-derivater - Google Patents

Farmaceutisk aktive isoindolin-derivater

Info

Publication number: DK2263669T3
Authority: DK; Denmark
Prior art keywords: pharmaceutically active; isoindoline derivatives; active isoindoline; derivatives; oxoisoindoline
Prior art date: 1999-11-12

Application number

DK10176420.7T

Other languages

English (en)

Inventor

Hon-Wah Man

George W Muller

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-12

Filing date

2000-11-09

Publication date

2012-04-23

2000-11-09 Application filed by Celgene Corp filed Critical Celgene Corp

2012-04-23 Application granted granted Critical

2012-04-23 Publication of DK2263669T3 publication Critical patent/DK2263669T3/da

Links

GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical class C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 title 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
QDZOBXFRIVOQBR-LJQANCHMSA-N n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-3-oxo-1h-isoindol-4-yl]cyclopropanecarboxamide Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(=O)C4CC4)C=CC=C3C2)=O)=C1 QDZOBXFRIVOQBR-LJQANCHMSA-N 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Biotechnology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK10176420.7T 1999-11-12 2000-11-09 Farmaceutisk aktive isoindolin-derivater DK2263669T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US16516899P	1999-11-12	1999-11-12
US59034400A	2000-06-08	2000-06-08
US09/708,199 US6667316B1 (en)	1999-11-12	2000-11-08	Pharmaceutically active isoindoline derivatives
EP06009632A EP1698334B1 (en)	1999-11-12	2000-11-09	Pharmaceutically active isoindoline derivatives

Publications (1)

Publication Number	Publication Date
DK2263669T3 true DK2263669T3 (da)	2012-04-23

Family

ID=27389110

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK00977095T DK1228071T3 (da)	1999-11-12	2000-11-09	Farmaceutisk aktive isoindolinderivater
DK10176420.7T DK2263669T3 (da)	1999-11-12	2000-11-09	Farmaceutisk aktive isoindolin-derivater

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK00977095T DK1228071T3 (da)	1999-11-12	2000-11-09	Farmaceutisk aktive isoindolinderivater

Country Status (19)

Country	Link
US (1)	US6667316B1 (da)
EP (4)	EP1698334B1 (da)
JP (1)	JP5116201B2 (da)
CN (1)	CN1325497C (da)
AT (4)	ATE544452T1 (da)
AU (2)	AU782409B2 (da)
CA (1)	CA2392081C (da)
CY (2)	CY1107610T1 (da)
DE (1)	DE60034139T2 (da)
DK (2)	DK1228071T3 (da)
ES (4)	ES2363933T3 (da)
FI (1)	FI119931B (da)
HK (1)	HK1049158A1 (da)
MX (1)	MXPA02004793A (da)
NO (2)	NO323633B1 (da)
NZ (1)	NZ519459A (da)
PT (2)	PT2263669E (da)
SI (1)	SI1228071T1 (da)
WO (1)	WO2001034606A1 (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6429221B1 (en)	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
US6518281B2 (en) *	1995-08-29	2003-02-11	Celgene Corporation	Immunotherapeutic agents
JP4214537B2 (ja) *	1996-08-12	2009-01-28	セルジーンコーポレーション	新規な免疫治療薬とこの薬物を使用してサイトカインレベルを抵減する方法
US8030343B2 (en) *	2000-06-08	2011-10-04	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US7491634B2 (en) *	2006-04-28	2009-02-17	Asm International N.V.	Methods for forming roughened surfaces and applications thereof
EP1389103A4 (en) *	2001-04-23	2005-09-14	Univ Virginia	SYNTHESIS AND EVALUATION OF NEW PHTHALIMIDE COPIES AS ANTIANGIOGENIC AGENTS
NZ531294A (en) *	2001-08-06	2005-11-25	Childrens Medical Center	Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) *	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2003097040A1 (en) *	2002-05-17	2003-11-27	Celgene Corporation	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7842691B2 (en)	2002-10-15	2010-11-30	Celgene Corporation	Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
US20050203142A1 (en) *	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en)	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
EP1567148A4 (en) *	2002-10-31	2010-09-15	Celgene Corp	METHOD OF USE AND COMPOSITIONS WITH SELECTIVE CYTOKINE INHIBITORS FOR THE TREATMENT AND SUPPLEMENT OF MACULAR DEGENERATION
US7776907B2 (en) *	2002-10-31	2010-08-17	Celgene Corporation	Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
KR20090048520A (ko) *	2002-11-06	2009-05-13	셀진 코포레이션	암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨 억제 약물의 사용 방법 및 그 조성물
US20060165649A1 (en) *	2002-11-06	2006-07-27	Zeldis Jerome B	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
AU2003294312A1 (en) *	2002-11-18	2004-07-09	Celgene Corporation	Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CA2506232A1 (en) *	2002-11-18	2004-06-03	Celgene Corporation	Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
JP5269281B2 (ja)	2002-12-30	2013-08-21	セルジーンコーポレイション	フルオロアルコキシ置換１，３−ジヒドロイソインドリル化合物およびそれらの医薬としての使用
US20040175382A1 (en) *	2003-03-06	2004-09-09	Schafer Peter H.	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
MXPA05009435A (es) *	2003-03-06	2005-11-23	Celgene Corp	Metodos de uso y composiciones que contienen medicamentos inhibidores selectivos de citocina para el tratamiento y manejo de alteraciones del sistema nervioso central.
CN100427465C (zh) *	2003-03-12	2008-10-22	细胞基因公司	N-烷基-异羟肟酸-异吲哚基化合物及其药物用途
CN1784382A (zh) *	2003-03-12	2006-06-07	细胞基因公司	7－氨基－异吲哚基化合物及其药物用途
ES2362484T3 (es) *	2003-03-12	2011-07-06	Celgene Corporation	Compuestos de ácido n-alquil-hidroxámico-isoindolilo y sus usos farmacéuticos.
EP1613269B1 (en)	2003-04-04	2015-02-25	Incyte Corporation	Compositions, methods and kits relating to her-2 cleavage
US7320992B2 (en) *	2003-08-25	2008-01-22	Amgen Inc.	Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
JP2007524656A (ja) *	2003-10-23	2007-08-30	セルジーン・コーポレーション	疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法
US20050142104A1 (en) *	2003-11-06	2005-06-30	Zeldis Jerome B.	Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
CN1972686A (zh) *	2004-04-14	2007-05-30	细胞基因公司	选择性细胞因子抑制药在髓发育不良综合征中的用途
WO2005102317A1 (en) *	2004-04-23	2005-11-03	Celgene Corporation	Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
EP1746989A4 (en) *	2004-05-05	2009-07-29	Celgene Corp	METHODS OF USE AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITION MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES
BRPI0418801A (pt) *	2004-05-05	2007-10-16	Celgene Corp	métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit
WO2006004191A1 (en) *	2004-07-05	2006-01-12	Astellas Pharma Inc.	Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
US7244759B2 (en) *	2004-07-28	2007-07-17	Celgene Corporation	Isoindoline compounds and methods of making and using the same
US20070190070A1 (en) *	2004-09-03	2007-08-16	Zeldis Jerome B	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
EP1794139A2 (en) *	2004-09-03	2007-06-13	Celgene Corporation	Substituted heterocyclic compounds and uses thereof
WO2006050057A2 (en) *	2004-10-28	2006-05-11	Celgene Corporation	Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
BRPI0519030A2 (pt) *	2004-12-13	2008-12-23	Celgene Corp	mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica
US20070155791A1 (en) *	2005-12-29	2007-07-05	Zeldis Jerome B	Methods for treating cutaneous lupus using aminoisoindoline compounds
MX2010010334A (es) *	2008-03-24	2010-10-08	Celgene Corp	Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
WO2010039538A2 (en)	2008-09-23	2010-04-08	Georgetown University	Flavivirus inhibitors and methods for their use
WO2010039545A2 (en) *	2008-09-23	2010-04-08	Georgetown University	1,2-benzisothiazolinone and isoindolinone derivatives
MY160002A (en)	2009-02-10	2017-02-15	Celgene Corp	Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
RU2536865C2 (ru)	2009-05-14	2014-12-27	Тяньцзинь Химэй Байо-Тек Ко., Лтд.	Производные тиофена
EA021019B1 (ru)	2009-06-18	2015-03-31	Концерт Фармасьютикалс, Инк.	Дейтерированные производные изоиндолин-1,3-диона
NZ599147A (en)	2009-10-09	2014-03-28	Celgene Corp	Processes for the preparation of 2-(1-phenylethyl) isoindolin-1-one compounds
RU2012131164A (ru) *	2009-12-22	2014-01-27	Селджин Корпорейшн	(метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение
US9408831B2 (en)	2010-04-07	2016-08-09	Celgene Corporation	Methods for treating respiratory viral infection
CN103026229B (zh)	2010-06-15	2016-03-30	细胞基因公司	用于治疗银屑病的生物标志物
WO2012096859A2 (en) *	2011-01-10	2012-07-19	Celgene Corporation	Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
CN103402980B (zh) *	2011-01-10	2016-06-29	细胞基因公司	作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
WO2012097116A2 (en)	2011-01-14	2012-07-19	Celgene Corporation	Isotopologues of isoindole derivatives
WO2012121988A2 (en)	2011-03-07	2012-09-13	Celgene Corporation	Methods for treating diseases using isoindoline compounds
US9428472B2 (en)	2011-08-16	2016-08-30	Georgetown University	Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
EP2765993B1 (en) *	2011-09-14	2020-05-20	Amgen (Europe) GmbH	Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2, 3-dihydro-1h-isoindol-4-yl}-amide
US8981117B2 (en)	2012-09-14	2015-03-17	Celgene Corporation	Processes for the preparation of isoindole compounds and isotopologues thereof
US20170087129A1 (en)	2014-05-16	2017-03-30	Celgene Corporation	Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
JP6687550B2 (ja)	2014-06-23	2020-04-22	セルジーンコーポレイション	肝疾患又は肝機能異常を治療するためのアプレミラスト
CN107635962A (zh) *	2015-03-19	2018-01-26	印度商西伯拉有限公司	用于制备阿普斯特的改进工艺
WO2017070291A1 (en)	2015-10-21	2017-04-27	Celgene Corporation	Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)
HU231259B1 (hu)	2016-02-04	2022-06-28	Egyt Gyogyszervegyeszeti Gyar	Eljárás pomalidomide elõállítására
RU2743126C9 (ru) *	2016-08-22	2021-04-27	Шицзячжуан Сагесити Нью Драг Дивелопмент Ко., Лтд.	Ингибитор pde4
CN107698484B (zh) *	2017-11-13	2020-05-19	广东中科药物研究有限公司	一种来那度胺的衍生物的制备方法与应用
WO2019142124A1 (en)	2018-01-17	2019-07-25	Cadila Healthcare Limited	Pharmaceutical compositions for treatment of vitiligo
AU2019254962C1 (en)	2018-04-17	2023-04-27	Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd	Isoindole derivatives
CN110746376B (zh) *	2018-07-22	2024-04-30	上海星叶医药科技有限公司	苯并异硒唑酮胺类化合物及其制备方法和用途
CN110003084B (zh) *	2019-03-15	2022-08-02	华南师范大学	一种同时具有力致发光和聚集诱导发光特性的有机圆偏振发光材料及其制备方法与应用
CN111170925B (zh) *	2020-01-09	2023-01-17	常州大学	作为pde2/4双重抑制剂的邻苯二甲酰亚胺类化合物及其制备方法
AU2021402911A1 (en) *	2020-12-14	2023-07-06	Biotheryx, Inc.	Pde4 degraders, pharmaceutical compositions, and therapeutic applications
EP4310079A4 (en) *	2021-03-15	2024-10-30	Shenzhen Forward Pharmaceuticals Co., Limited	ESTROGEN RECEPTOR ANTAGONIST
CN114790164B (zh)	2021-08-13	2022-12-27	苏州璞正医药有限公司	一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途
CN116354857B (zh) *	2023-03-01	2025-01-21	中国人民解放军海军军医大学	一种β-氨基砜及其衍生物的制备方法
CN120000646A (zh) *	2023-11-14	2025-05-16	天津合美医药科技有限公司	干燥综合征的预防或治疗
WO2025103426A1 (zh) *	2023-11-14	2025-05-22	赣州和美药业股份有限公司	白塞综合征的治疗

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4173652A (en)	1976-12-18	1979-11-06	Akzona Incorporated	Pharmaceutical hydroxamic acid compositions and uses thereof
SE434638B (sv)	1980-06-06	1984-08-06	Lekemedelsfabriken Medica Ab	Nya terapeutiska verdefulla taurinderivat och deras framstellning
US4820828A (en)	1987-03-04	1989-04-11	Ortho Pharmaceutical Corporation	Cinnamohydroxamic acids
US5463063A (en) *	1993-07-02	1995-10-31	Celgene Corporation	Ring closure of N-phthaloylglutamines
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
US5605914A (en)	1993-07-02	1997-02-25	Celgene Corporation	Imides
US5703098A (en)	1994-12-30	1997-12-30	Celgene Corporation	Immunotherapeutic imides/amides
US6429221B1 (en) *	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
US5801195A (en)	1994-12-30	1998-09-01	Celgene Corporation	Immunotherapeutic aryl amides
WO1997005105A1 (en)	1995-07-26	1997-02-13	Pfizer Inc.	N-(aroyl)glycine hydroxamic acid derivatives and related compounds
US5728844A (en) *	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
US5728845A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic nitriles
US5658940A (en)	1995-10-06	1997-08-19	Celgene Corporation	Succinimide and maleimide cytokine inhibitors
WO1997024117A1 (en)	1996-01-02	1997-07-10	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
PT968182E (pt) *	1996-08-07	2004-08-31	Darwin Discovery Ltd	Derivados de acidos hidroxamicos e carboxilicos com actividade inibidora da mpm e do fnt
JP4214537B2 (ja)	1996-08-12	2009-01-28	セルジーンコーポレーション	新規な免疫治療薬とこの薬物を使用してサイトカインレベルを抵減する方法
JP2001511448A (ja) *	1997-07-31	2001-08-14	セルジーンコーポレイション	置換アルカノヒドロキサム酸およびＴＮＦαレベルの減少方法
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels

2000
- 2000-11-08 US US09/708,199 patent/US6667316B1/en not_active Expired - Lifetime
- 2000-11-09 ES ES06009632T patent/ES2363933T3/es not_active Expired - Lifetime
- 2000-11-09 AT AT10176420T patent/ATE544452T1/de active
- 2000-11-09 DK DK00977095T patent/DK1228071T3/da active
- 2000-11-09 MX MXPA02004793A patent/MXPA02004793A/es active IP Right Grant
- 2000-11-09 HK HK03100819.6A patent/HK1049158A1/zh unknown
- 2000-11-09 EP EP06009632A patent/EP1698334B1/en not_active Expired - Lifetime
- 2000-11-09 EP EP10176420A patent/EP2263669B1/en not_active Expired - Lifetime
- 2000-11-09 ES ES00977095T patent/ES2282147T3/es not_active Expired - Lifetime
- 2000-11-09 ES ES10176390T patent/ES2381174T3/es not_active Expired - Lifetime
- 2000-11-09 NZ NZ519459A patent/NZ519459A/en not_active IP Right Cessation
- 2000-11-09 AT AT00977095T patent/ATE357913T1/de active
- 2000-11-09 EP EP00977095A patent/EP1228071B8/en not_active Expired - Lifetime
- 2000-11-09 AT AT06009632T patent/ATE506058T1/de not_active IP Right Cessation
- 2000-11-09 SI SI200030951T patent/SI1228071T1/sl unknown
- 2000-11-09 EP EP10176390A patent/EP2255801B1/en not_active Expired - Lifetime
- 2000-11-09 ES ES10176420T patent/ES2380574T3/es not_active Expired - Lifetime
- 2000-11-09 PT PT10176420T patent/PT2263669E/pt unknown
- 2000-11-09 PT PT00977095T patent/PT1228071E/pt unknown
- 2000-11-09 JP JP2001536553A patent/JP5116201B2/ja not_active Expired - Fee Related
- 2000-11-09 AT AT10176390T patent/ATE544451T1/de active
- 2000-11-09 CA CA002392081A patent/CA2392081C/en not_active Expired - Fee Related
- 2000-11-09 AU AU14780/01A patent/AU782409B2/en not_active Ceased
- 2000-11-09 DE DE60034139T patent/DE60034139T2/de not_active Expired - Lifetime
- 2000-11-09 WO PCT/US2000/030770 patent/WO2001034606A1/en not_active Ceased
- 2000-11-09 CN CNB00818254XA patent/CN1325497C/zh not_active Expired - Fee Related
- 2000-11-09 DK DK10176420.7T patent/DK2263669T3/da active
2002
- 2002-05-08 NO NO20022223A patent/NO323633B1/no not_active IP Right Cessation
- 2002-05-10 FI FI20020892A patent/FI119931B/fi not_active IP Right Cessation
2005
- 2005-07-07 AU AU2005202964A patent/AU2005202964B2/en not_active Ceased
2007
- 2007-03-21 NO NO20071490A patent/NO336210B1/no not_active IP Right Cessation
- 2007-04-05 CY CY20071100487T patent/CY1107610T1/el unknown
2012
- 2012-04-26 CY CY20121100399T patent/CY1112707T1/el unknown

Also Published As

Publication number	Publication date
EP2263669A1 (en)	2010-12-22
FI20020892A0 (fi)	2002-05-10
JP5116201B2 (ja)	2013-01-09
PT2263669E (pt)	2012-04-23
FI119931B (fi)	2009-05-15
ATE357913T1 (de)	2007-04-15
DE60034139T2 (de)	2007-12-06
FI20020892L (fi)	2002-06-20
EP2255801B1 (en)	2012-02-08
ES2282147T3 (es)	2007-10-16
AU2005202964A1 (en)	2005-08-11
NO20022223D0 (no)	2002-05-08
HK1049158A1 (zh)	2003-05-02
DE60034139D1 (de)	2007-05-10
NO20071490L (no)	2002-07-08
SI1228071T1 (sl)	2007-08-31
CY1112707T1 (el)	2016-02-10
DK1228071T3 (da)	2007-08-06
EP1228071A1 (en)	2002-08-07
EP1698334A1 (en)	2006-09-06
PT1228071E (pt)	2007-05-31
ATE506058T1 (de)	2011-05-15
MXPA02004793A (es)	2003-10-14
NO336210B1 (no)	2015-06-15
CA2392081C (en)	2010-01-05
AU1478001A (en)	2001-06-06
AU782409B2 (en)	2005-07-28
ATE544452T1 (de)	2012-02-15
CY1107610T1 (el)	2013-03-13
AU2005202964B2 (en)	2007-11-22
CN1420889A (zh)	2003-05-28
ES2363933T3 (es)	2011-08-19
EP2255801A1 (en)	2010-12-01
EP1228071B8 (en)	2012-02-29
EP1228071B1 (en)	2007-03-28
EP1228071A4 (en)	2002-12-04
ATE544451T1 (de)	2012-02-15
NO323633B1 (no)	2007-06-18
ES2380574T3 (es)	2012-05-16
US6667316B1 (en)	2003-12-23
WO2001034606A1 (en)	2001-05-17
CA2392081A1 (en)	2001-05-17
NO20022223L (no)	2002-07-08
JP2004500346A (ja)	2004-01-08
HK1053467A1 (en)	2003-10-24
NZ519459A (en)	2003-11-28
CN1325497C (zh)	2007-07-11
EP2263669B1 (en)	2012-02-08
ES2381174T3 (es)	2012-05-23
EP1698334B1 (en)	2011-04-20

Publication	Publication Date	Title
ATE544452T1 (de)	2012-02-15	Pharmazeutisch aktive isoindolin-derivate
CY1123084T1 (el)	2021-10-29	Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
NO20002217D0 (no)	2000-04-28	Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
DE60045168D1 (de)	2010-12-09	Kombinationspräparate enthaltend (E)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r,5s)-3,5-dihydroxyhept-6-enoic Säure
DK0479903T3 (da)	1996-03-18	Substituerede imidazoler og deres anvendelse som angiotensin II hæmmere
ES2172143T3 (es)	2002-09-16	Combinaciones de productos activos fungicidas.
DK1206261T3 (da)	2006-07-03	Farmaceutiske præparater, der omfatter clavuansyre eller derivater deraf, til behandlingen af adfærdsmæssige sygdomme
HRP20000494B1 (en)	2009-02-28	Pharmaceutically active morpholinol
AU2001296865A1 (en)	2002-03-22	(5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
DK0998287T3 (da)	2003-09-01	Anvendelse af levobupivacain
EP1295611A4 (en)	2009-07-08	COMPOUNDS FOR THE TRANSFER OF OLIGONUCLEOTIDES (03.01.02)
EA200101150A1 (ru)	2002-04-25	Раствор прукалоприда для перорального применения
EA200400877A1 (ru)	2005-02-24	2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи
IT1306706B1 (it)	2001-10-02	Articolatore perfezionato per la realizzazione di modelli in gesso.
RU2000106182A (ru)	2002-01-27	Средство для лечения поражения кожи различной этиологии
SE9902742D0 (sv)	1999-07-20	New pharmaceutical formultion
DE69807200D1 (de)	2002-09-19	Inklusionskomplexe in waessriger loesung
DK1086695T3 (da)	2005-04-25	Antivirale præparater omfattende yohimbin som aktivt princip
ATE302582T1 (de)	2005-09-15	Haartonikum mit l-arginin als wirkstoff
IT1310896B1 (it)	2002-02-27	Articolatore per odontotecnica.
EP1210949A4 (en)	2003-03-19	MEDIUM WITH ANTIULCUS EFFECT
IT1311630B1 (it)	2002-03-14	Perfezionamento ad una struttura di vassoio isotermico,particolarmente per la somministrazione delle vivande alle comunita'.
ITBO990038A0 (it)	1999-01-28	Pomata per la cura delle lesioni cutanee particolarmente delle ustioni .
ES1044269Y (es)	2000-09-01	Mesa camilla desmontable.
ES1044586Y (es)	2000-09-16	Limpiazapatos perfeccionado.